Edgewise Therapeutics Stock Gains After Corporate Update
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.
Topic
Latest reporting and analysis tagged with Edgewise Therapeutics.
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.